Purpose of the development: Early diagnosis of cancer and leukemia. Differential diagnosis of tumors. Revealing of metastases. Evaluation of the immunological status. AIDS monitoring. Control of the effectiveness of treatment of patients.

Recommended application field: Medicine. Diagnosis of cancer and leukemia.

Advantages over analogues: There are no domestic analogs for development.

The development stage readiness: Ready for application

Technical and economic effect: In terms of specificity and quality, domestic MKATs are not inferior to foreign analogues at a significantly lower cost.

Description of the development:
()
Sets of purified monoclonal antibodies (MBAT) produced by the hybridoma. The hybridoma collection includes the clitoris derivatives of MKAT to CD3, CD4, CD7, CD8, CD10, CD13, CD15, CD16, CD20, CD22, CD25, CD27, CD34, CD45, CD45RA, CD48, CD54, CD56, CD66e , CD95, CD150, CD227, CD326, HLA-ABC, HLA-DR, kappa and lambda light chains of immunoglobulins, pan-cytokeratin, cytokeratin-18, p53 and IPO-38. Development is included in the State Register of Medical Devices and authorized for use in Ukraine (perpetual license). On request, manufacturing, cleaning, testing of specificity, supply and quality assurance of MKAT, training of personnel is carried out.

Information about newness of the development:
there are Ukrainian patents -- 1 items

ноу-хау--
1 шт.

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level
Creation of joint enterprise

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua